Semaglutide Research & Studies
Part of the full Semaglutide guide - a acylated glp-1 receptor agonist reference compound, identity-verified with a COA on every vial.
In brief
The research record attached to semaglutide in the provided entry centers on four primary-literature sources that together map the molecule from discovery chemistry through high-resolution structural pharmacology. These are the Lau et al. 2015 Journal of Medicinal Chemistry discovery paper, the Knudsen and Lau 2019 Frontiers in Endocrinology development review, the Zhang et al. 2021 Cell Reports cryo-EM study of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes, and the Zhang et al. 2017 Nature cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. The listed research areas are correspondingly biochemical and structural: GLP-1R agonist binding and structural pharmacology, Galpha-s/adenylate-cyclase/cyclic-AMP signal transduction, beta-arrestin recruitment and biased-agonism profiling, DPP-4 enzymatic-stability assays, albumin-binding acylation and protraction mechanisms, and cryo-EM structural dynamics. This spoke describes what those specific sources and in-vitro model contexts actually investigate, attributed only to the citations provided.
The detail
A closer look
01
Discovery chemistry and stability characterization
The foundational source, Lau et al. 2015 (J Med Chem, PMID 26308095), is the discovery paper for the once-weekly GLP-1 analogue. It is the citation the entry ties to the reported recombinant GLP-1R binding affinity of approximately 0.38 nM and to the rationale for the key structural modifications: the Aib8 substitution conferring DPP-4 resistance, the Arg34 change that directs site-specific acylation, and the Lys26 C18 fatty-diacid acylation via the gamma-Glu/OEG linker for albumin binding. The associated research areas frame this work in in-vitro peptidase-stability assays (DPP-4 resistance) and albumin-binding protraction studies. Knudsen and Lau 2019 (Front Endocrinol, PMID 31031702) provides the development-review context, and is the source cited for the backbone identity as a 31-residue analogue of human GLP-1(7-37) with roughly 94% sequence homology. Together these define the structure-activity logic underpinning the molecule.
02
Structural biology of the receptor complex
Two cryo-electron microscopy studies anchor the structural research. Zhang et al. 2021 (Cell Reports, PMID 34260945) resolved structures and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes; the entry attributes to this work the depiction of canonical Gs coupling and the sharp kink in transmembrane helix 6 that marks the active state, and cites it for the receptor/target-class designation as a class B Gs-coupled GPCR. Zhang et al. 2017 (Nature, PMID 28538729) reported the cryo-EM structure of the activated GLP-1 receptor in complex with a G protein, providing the broader structural template for how this class B receptor adopts its active conformation. The corresponding research areas, cryo-EM structural dynamics of peptide-GLP-1R-Gs complexes and class B GPCR agonist structural pharmacology, situate the molecule within a structure-led investigative program rather than a phenotypic one.
03
Signaling and comparative pharmacology context
Beyond binding and structure, the listed research areas describe the in-vitro signaling assays used to profile the molecule in GLP-1R-expressing cells: Galpha-s/adenylate-cyclase/cyclic-AMP signal transduction as the primary potency readout, beta-arrestin recruitment, and biased-agonism profiling. The mechanism data also note PKA and Epac2 effector pathways and Gq-dependent components observed in these cellular models. A further research area is comparative GLP-1R agonist receptor-affinity and potency characterization, the framework within which the approximately 0.38 nM affinity is interpreted and within which the Zhang 2021 study positions semaglutide alongside taspoglutide. All of these contexts are recombinant or cell-based receptor-pharmacology systems; the provided sources describe biochemical, structural, and cell-signaling endpoints, not clinical outcomes, and no additional studies beyond the four cited may be referenced.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Semaglutide is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.